There was a tendency of cholecalciferol-treated patients to have high CD8+ cytotoxic T-lymphocyte and CD16+CD56+ natural killer cell counts in the absence of clinical symptoms or indications of infection, suggesting high immunocompetence of cholecalciferol-treated patients (Tables 1 and 2). The gene discussed is NCAM1; the disease is infection.